Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Avidity Biosciences (RNA) over the last 7 years, with Q3 2025 value amounting to -$156.9 million.

  • Avidity Biosciences' Free Cash Flow fell 13304.71% to -$156.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$592.3 million, marking a year-over-year decrease of 21417.95%. This contributed to the annual value of -$307.9 million for FY2024, which is 14976.15% down from last year.
  • According to the latest figures from Q3 2025, Avidity Biosciences' Free Cash Flow is -$156.9 million, which was down 13304.71% from -$203.0 million recorded in Q2 2025.
  • Over the past 5 years, Avidity Biosciences' Free Cash Flow peaked at $15.6 million during Q4 2023, and registered a low of -$203.0 million during Q2 2025.
  • In the last 5 years, Avidity Biosciences' Free Cash Flow had a median value of -$40.0 million in 2022 and averaged -$60.9 million.
  • As far as peak fluctuations go, Avidity Biosciences' Free Cash Flow soared by 13905.69% in 2023, and later plummeted by 76368.46% in 2024.
  • Over the past 5 years, Avidity Biosciences' Free Cash Flow (Quarter) stood at -$27.9 million in 2021, then plummeted by 43.4% to -$40.0 million in 2022, then skyrocketed by 139.06% to $15.6 million in 2023, then tumbled by 763.68% to -$103.8 million in 2024, then plummeted by 51.16% to -$156.9 million in 2025.
  • Its Free Cash Flow stands at -$156.9 million for Q3 2025, versus -$203.0 million for Q2 2025 and -$128.6 million for Q1 2025.